<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05069597</url>
  </required_header>
  <id_info>
    <org_study_id>M21-432</org_study_id>
    <nct_id>NCT05069597</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon</brief_title>
  <official_title>A Phase 4 Study to Assess Symptoms of Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis or Chronic Pancreatitis Treated With CreonÂ® (Pancrelipase) With an Alternate Source of Active Pharmaceutical Ingredient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exocrine pancreatic insufficiency (EPI) is a condition that is caused by the inadequate&#xD;
      pancreatic enzymes needed for normal digestion and is commonly associated with a wide range&#xD;
      of chronic diseases, including cystic fibrosis (CF), chronic pancreatitis (CP), and&#xD;
      pancreatic cancer. This study will assess clinical symptoms when participants with CF or CP&#xD;
      are treated with Creon with alternate source of active drug.&#xD;
&#xD;
      Creon is an approved drug for the treatment of EPI due to CF or CP. This study is&#xD;
      subject-blinded which means participants will not know the source of the study drug they are&#xD;
      given. Approximately 30 adult participants with CF or CP will be enrolled at approximately 15&#xD;
      sites across the Unites States.&#xD;
&#xD;
      Participants will receive oral capsules of CREON for 112 days and will be followed for 30&#xD;
      days.&#xD;
&#xD;
      Participants will attend regular visits during the study at a hospital or clinic or via&#xD;
      telemedicine. The effect of the treatment will be checked by medical assessments, checking&#xD;
      for side effects and completing questionnaires.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptoms of Exocrine Pancreatic Insufficiency (EPI)</measure>
    <time_frame>Day 1 through Day 85</time_frame>
    <description>Mean symptom scores will be summarized.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Chronic Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Run-in Period: Creon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Creon daily for 112 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Period: Creon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Creon daily for 112 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CREON</intervention_name>
    <description>Capsule; Oral</description>
    <arm_group_label>Run-in Period: Creon</arm_group_label>
    <arm_group_label>Treatment Period: Creon</arm_group_label>
    <other_name>Pancrelipase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previous diagnosis of cystic fibrosis (CF) or chronic pancreatitis (CP).&#xD;
&#xD;
          -  Previous diagnosis of exocrine pancreatic insufficiency (EPI) that is currently&#xD;
             clinically controlled.&#xD;
&#xD;
          -  Total Symptom Score (TSS) &lt; 1.8 on Pancreatic Exocrine Insufficiency Questionnaire&#xD;
             (PEI-Q) at Screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Malignancy involving the digestive tract in the last 5 years, or other significant&#xD;
        disease or medical condition that may interfere with EPI symptom assessment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>MedPharmics, LLC - Mobile /ID# 231076</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608-1771</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Florida - Archer /ID# 233411</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Encore Borland-Groover Clinical Research /Id# 239368</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atlantic Medical Research Group /ID# 239568</name>
      <address>
        <city>Margate</city>
        <state>Florida</state>
        <zip>33063-5737</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Miami, Miller School of Medicine /ID# 239415</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>GI Pros /ID# 239486</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102-5449</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMass Memorial Medical Center /ID# 230476</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Curators of the University of Missouri /ID# 233331</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Children's Mercy Hospital /ID# 230479</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center /ID# 231633</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NYU Langone Health /ID# 233417</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016-2708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health /ID# 229537</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-0001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati /ID# 229511</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0585</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Options Health Research, LLC /ID# 239535</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine Medical Center /ID# 233441</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>West Virginia University Hospitals /ID# 239593</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.rxabbvie.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Chronic Pancreatitis</keyword>
  <keyword>Exocrine Pancreatic Insufficiency</keyword>
  <keyword>Creon</keyword>
  <keyword>Pancrelipase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatitis, Chronic</mesh_term>
    <mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancrelipase</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>For details on when studies are available for sharing, please refer to the link below.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/abbvie/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

